|
1
|
Marchio C, Balmativola D, Castiglione R,
Annaratone L and Sapino A: Predictive diagnostic pathology in the
target therapy era in breast cancer. Curr Drug Targets. 18:4–12.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Mardekian SK, Bombonati A and Palazzo JP:
Ductal carcinoma in situ of the breast: The importance of
morphologic and molecular interactions. Hum Pathol. 49:114–23.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sørlie T, Perou CM, Tibshirani R, Aas T,
Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey
SS, et al: Gene expression patterns of breast carcinomas
distinguish tumor subclasses with clinical implications. Proc Natl
Acad Sci USA. 98:10869–10874. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
El-Rehim Abd DM, Ball G, Pinder SE, Rakha
E, Paish C, Robertson JF, Macmillan D, Blamey RW and Ellis IO:
High-throughput protein expression analysis using tissue microarray
technology of a large well-characterised series identifies
biologically distinct classes of breast cancer confirming recent
cDNA expression analyses. Int J Cancer. 116:340–350. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Cheang MC, Chia SK, Voduc D, Gao D, Leung
S, Snider J, Watson M, Davies S, Bernard PS, Parker JS, et al: Ki67
index, HER2 status, and prognosis of patients with luminal B breast
cancer. J Natl Cancer Inst. 101:736–750. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Tang P and Tse GM: Immunohistochemical
surrogates for molecular classification of breast carcinoma: A 2015
update. Arch Pathol Lab Med. 140:806–814. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hagemann IS: Molecular testing in breast
cancer: A guide to current practices. Arch Pathol Lab Med.
140:815–824. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Tan W, Li Q, Chen K, Su F, Song E and Gong
C: Estrogen receptor beta as a prognostic factor in breast cancer
patients: A systematic review and meta-analysis. Oncotarget.
7:10373–10385. 2016.PubMed/NCBI
|
|
9
|
Matsumoto A, Jinno H, Ando T, Fujii T,
Nakamura T, Saito J, Takahashi M, Hayashida T and Kitagawa Y:
Biological markers of invasive breast cancer. Jpn J Clin Oncol.
46:99–105. 2016.PubMed/NCBI
|
|
10
|
Lehmann U, Albat C and Kreipe H:
High-resolution quantitative methylation analysis of microRNA genes
using Pyrosequencing™. Methods Mol Biol. 878:229–240. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hennessy BT, Gonzalez-Angulo AM,
Stemke-Hale K, Gilcrease MZ, Krishnamurthy S, Lee JS, Fridlyand J,
Sahin A, Agarwal R, Joy C, et al: Characterization of a naturally
occurring breast cancer subset enriched in
epithelial-to-mesenchymal transition and stem cell characteristics.
Cancer Res. 69:4116–4124. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lin X, Shang X, Manorek G and Howell SB:
Regulation of the epithelial-mesenchymal transition by claudin-3
and claudin-4. PLoS One. 8:e674962013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lu S, Singh K, Mangray S, Tavares R, Noble
L, Resnick MB and Yakirevich E: Claudin expression in high-grade
invasive ductal carcinoma of the breast: Correlation with the
molecular subtype. Mod Pathol. 26:485–495. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Prat A, Parker JS, Karginova O, Fan C,
Livasy C, Herschkowitz JI, He X and Perou CM: Phenotypic and
molecular characterization of the claudin-low intrinsic subtype of
breast cancer. Breast Cancer Res. 12:R682010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Singh AB and Dhawan P: Claudins and
cancer: Fall of the soldiers entrusted to protect the gate and keep
the barrier intact. Semin Cell Dev Biol. 42:58–65. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Khan N and Asif AR: Transcriptional
regulators of claudins in epithelial tight junctions. Mediators
Inflamm. 2015:2198432015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Achari C, Winslow S and Larsson C: Down
regulation of CLDND1 induces apoptosis in breast cancer cells. PLoS
One. 10:e01303002015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Iravani O, Yip GW, Thike AA, Chua PJ,
Scully Jane O, Tan PH and Bay BH: Prognostic significance of
Claudin 12 in estrogen receptor-negative breast cancer. J Clin
Pathol. 69:878–883. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Katayama A, Handa T, Komatsu K, Togo M,
Horiguchi J, Nishiyama M and Oyama T: Expression patterns of
claudins in patients with triple-negative breast cancer are
associated with nodal metastasis and worse outcome. Pathol Int.
67:404–413. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Dias K, Dvorkin-Gheva A, Hallett RM, Wu Y,
Hassell J, Pond GR, Levine M, Whelan T and Bane AL: Claudin-low
breast cancer; clinical and pathological characteristics. PLoS One.
12:e01686692017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lanigan F, McKiernan E, Brennan DJ,
Hegarty S, Millikan RC, McBryan J, Jirstrom K, Landberg G, Martin
F, Duffy MJ and Gallagher WM: Increased claudin-4 expression is
associated with poor prognosis and high tumour grade in breast
cancer. Int J cancer. 124:2088–2097. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Gerhard R, Ricardo S, Albergaria A, Gomes
M, Silva AR, Logullo ÂF, Cameselle-Teijeiro JF, Paredes J and
Schmitt F: Immunohistochemical features of claudin-low intrinsic
subtype in metaplastic breast carcinomas. Breast. 21:354–360. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Rakha EA, El-Sayed ME, Lee AH, Elston CW,
Grainge MJ, Hodi Z, Blamey RW and Ellis IO: Prognostic significance
of nottingham histologic grade in invasive breast carcinoma. J Clin
Oncol. 26:3153–3158. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Mangone FR, Brentani MM, Nonogaki S,
Begnami MD, Campos AH, Walder F, Carvalho MB, Soares FA, Torloni H,
Kowalski LP and Federico MH: Overexpression of Fos-related
antigen-1 in head and neck squamous cell carcinoma. Int J Exp
Pathol. 86:205–212. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Allred DC, Harvey JM, Berardo M and Clark
GM: Prognostic and predictive factors in breast cancer by
immunohistochemical analysis. Mod Pathol. 11:155–168.
1998.PubMed/NCBI
|
|
26
|
Wolff AC, Hammond ME, Hicks DG, Dowsett M,
McShane LM, Allison KH, Allred DC, Bartlett JM, Bilous M,
Fitzgibbons P, et al: Recommendations for human epidermal growth
factor receptor 2 testing in breast cancer: American Society Of
Clinical Oncology/College of American Pathologists clinical
practice guideline update. Arch Pathol Lab Med. 138:241–256. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wolff AC, Hammond ME, Hicks DG, Dowsett M,
McShane LM, Allison KH, Allred DC, Bartlett JM, Bilous M,
Fitzgibbons P, et al: Recommendations for human epidermal growth
factor receptor 2 testing in breast cancer: American Society of
Clinical Oncology/College of American Pathologists clinical
practice guideline update. J Clin Oncol. 31:3997–4013. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Bernardi MA, Logullo AF, Pasini FS,
Nonogaki S, Blumke C, Soares FA and Brentani MM: Prognostic
significance of CD24 and claudin-7 immunoexpression in ductal
invasive breast cancer. Oncol Rep. 27:28–38. 2012.PubMed/NCBI
|
|
29
|
Carey LA, Perou CM, Livasy CA, Dressler
LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S,
et al: Race, breast cancer subtypes, and survival in the Carolina
breast cancer study. JAMA. 295:2492–2502. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Blanchard AA, Zelinski T, Xie J, Cooper S,
Penner C, Leygue E and Myal Y: Identification of claudin 1
transcript variants in human invasive breast cancer. PLoS One.
11:e01633872016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Blanchard AA, Skliris GP, Watson PH,
Murphy LC, Penner C, Tomes L, Young TL, Leygue E and Myal Y:
Claudins 1, 3, and 4 protein expression in ER negative breast
cancer correlates with markers of the basal phenotype. Virchows
Arch. 454:647–656. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Morohashi S, Kusumi T, Sato F, Odagiri H,
Chiba H, Yoshihara S, Hakamada K, Sasaki M and Kijima H: Decreased
expression of claudin-1 correlates with recurrence status in breast
cancer. Int J Mol Med. 20:139–143. 2007.PubMed/NCBI
|
|
33
|
Kwon MJ: Emerging roles of claudins in
human cancer. Int J Mol Sci. 14:18148–18180. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kominsky SL, Argani P, Korz D, Evron E,
Raman V, Garrett E, Rein A, Sauter G, Kallioniemi OP and Sukumar S:
Loss of the tight junction protein claudin-7 correlates with
histological grade in both ductal carcinoma in situ and invasive
ductal carcinoma of the breast. Oncogene. 22:2021–2033. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Soini Y: Expression of claudins 1, 2, 3,
4, 5 and 7 in various types of tumours. Histopathology. 46:551–560.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Tokés AM, Kulka J, Paku S, Szik A, Páska
C, Novák PK, Szilák L, Kiss A, Bögi K and Schaff Z: Claudin-1, −3
and −4 proteins and mRNA expression in benign and malignant breast
lesions: a research study. Breast Cancer Res. 7:R296–R305. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Kolokytha P, Yiannou P, Keramopoulos D,
Kolokythas A, Nonni A, Patsouris E and Pavlakis K: Claudin-3 and
claudin-4: Distinct prognostic significance in triple-negative and
luminal breast cancer. Appl Immunohistochem Mol Morphol.
22:125–131. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Prat A and Perou CM: Deconstructing the
molecular portraits of breast cancer. Mol Oncol. 5:5–23. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Sabatier R, Finetti P, Guille A, Adelaide
J, Chaffanet M, Viens P, Birnbaum D and Bertucci F: Claudin-low
breast cancers: Clinical, pathological, molecular and prognostic
characterization. Mol Cancer. 13:2282014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Szasz AM, Nemeth Z, Gyorffy B, Micsinai M,
Krenacs T, Baranyai Z, Harsanyi L, Kiss A, Schaff Z, Tokes AM and
Kulka J: Identification of a claudin-4 and E-cadherin score to
predict prognosis in breast cancer. Cancer Sci. 102:2248–2254.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Myal Y, Leygue E and Blanchard AA: Claudin
1 in breast tumorigenesis: Revelation of a possible novel ‘claudin
high’ subset of breast cancers. J Biomed Biotechnol.
2010:9568972010. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Kulka J, Szász AM, Németh Z, Madaras L,
Schaff Z, Molnár IA and Tokés AM: Expression of tight junction
protein claudin-4 in basal-like breast carcinomas. Pathol Oncol
Res. 15:59–64. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Prat A, Karginova O, Parker JS, Fan C, He
X, Bixby L, Harrell JC, Roman E, Adamo B, Troester M and Perou CM:
Characterization of cell lines derived from breast cancers and
normal mammary tissues for the study of the intrinsic molecular
subtypes. Breast Cancer Res Treat. 142:237–255. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Sauer T, Pedersen MK, Ebeltoft K and Naess
O: Reduced expression of Claudin-7 in fine needle aspirates from
breast carcinomas correlate with grading and metastatic disease.
Cytopathology. 16:193–198. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Park D, Kåresen R, Axcrona U, Noren T and
Sauer T: Expression pattern of adhesion molecules ((E-cadherin,
alpha-, beta-, gamma-catenin and claudin-7), their influence on
survival in primary breast carcinoma, and their corresponding
axillary lymph node metastasis. APMIS. 115:52–65. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Farahani E, Patra HK, Jangamreddy JR,
Rashedi I, Kawalec M, Pariti Rao RK, Batakis P and Wiechec E: Cell
adhesion molecules and their relation to (cancer) cell stemness.
Carcinogenesis. 35:747–759. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Giuliano AE, Connolly JL, Edge SB,
Mittendorf EA, Rugo HS, Solin LJ, Weaver DL, Winchester DJ and
Hortobagyi GN: Breast cancer-major changes in the American Joint
Committee on Cancer eighth edition cancer staging manual. CA Cancer
J Clin. 67:290–303. 2017. View Article : Google Scholar : PubMed/NCBI
|
